v3.26.3
Sale of PerClot (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jul. 28, 2021
Jan. 31, 2026
Dec. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Disposal Group, Including Discontinued Operations [Line Items]                  
Total revenues       $ 123,790 $ 113,388   $ 365,884 $ 325,338  
Gain from sale of non-financial assets       0 3,500   0 3,500  
Per Clot                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Consideration for sale of assets $ 41,000                
Proceeds from sale of assets           $ 5,000      
Proceeds from divestiture                 $ 5,000
Total revenues       2,500 600   4,900 2,400  
Gain from sale of non-financial assets         $ 3,500 7,000   $ 3,500  
Notes and loans receivable       5,000     5,000    
Per Clot | Forecast                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Proceeds from sale of assets     $ 5,000            
Per Clot | Transfer Of Perclot Manufacturing Equipment                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Contingent consideration receivable 800                
Per Clot | Upon Our Receipt of Premarket Approval                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Proceeds from sale of assets 18,800                
Per Clot | Starch Medical Inc.                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Contingent liability payment 4,500 $ 1,500              
Payable       $ 1,500   $ 3,000 $ 1,500   $ 3,000
Per Clot | Artivion Inc. And Starch Medical Inc.                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Consideration for sale of assets 54,500                
Proceeds from sale of assets 25,000                
Per Clot | Artivion Inc. And Starch Medical Inc. | Baxter Achievement Of Worldwide Sales                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Contingent consideration receivable $ 10,000                
Contractual period 24 months                
Per Clot | Starch Medical Inc.                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Consideration for sale of assets $ 13,500                
Contingent liability payment 6,000                
Per Clot | Starch Medical Inc. | Baxter Achievement Of Worldwide Sales                  
Disposal Group, Including Discontinued Operations [Line Items]                  
Contingent liability payment $ 3,000